# 23andMe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/23andme

- Industry: Biotechnology
- Headquarters: Sunnyvale, US
- Website: www.23andme.com
- Total disclosed funding: $523M
- Latest round: Series F (Dec 9, 2020)
- Investors on record: 20

## About

Based in California, US, 23andMe, Inc. was founded in 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. 23andMe is a privately held personal genomics and biotechnology company and is known for providing a direct-to-consumer genetic testing service. The company has been selling products with ancestry and health-related components in Canada since October 2014 and in the UK since December 2014. 23andMe is the first company to begin offering autosomal DNA testing for ancestry in 2007. In October 2020, the company offered a new service called 23andMe+, this makes available additional reports on health and pharmacogenetics and provides ongoing new reports. In October 2021, the firm a portfolio company of Altimeter Capital Management, Euclidean Capital, Fidelity Investments, Foundation Asset Management, G Squared, GSK Ventures, National Human Genome Research Institute, NewView Capital, Pegasus Tech Ventures, Roche Venture Fund, SharesPost, and Xfund acquired LMND Medical Group, Inc. from 415 Ventures, Adaptive Health Capital, Correlation Ventures, Hikma Ventures, Novartis Venture Fund, Vega Ventures, ARTIS Ventures, Endurance Companies, Health Velocity Capital, OTV, and Sierra Ventures for 400 million dollars.

23andMe, Inc. platform is offering gene indexing while highlighting important findings through web-based tools and allows patients to have insights into personal ancestry, genealogy, and inherited traits.

## Funding rounds

- Series F, Dec 9, 2020, $83M — Hong Shan, NewView Capital
- Series F, Aug 31, 2017, $250M — Hong Shan, Fidelity Investments, FAM, Casdin Capital, G Squared, Altimeter Capital, Euclidean Capital
- Series E, Jun 18, 2015, $79M — New Enterprise Associates, MPM BioImpact, Fidelity Investments, GV, Illumina, Inc., Casdin Capital, Xfund, 6 Dimensions Capital, EquityZen, ZWC Ventures
- Series D, Dec 10, 2012, $58M — New Enterprise Associates, MPM BioImpact, GV
- Series C, Jan 7, 2011, $5.6M — New Enterprise Associates, Johnson & Johnson Innovation, MPM BioImpact, GV, Roche Venture Fund
- Series C, Nov 5, 2010, $22M — New Enterprise Associates, Johnson & Johnson Innovation, GV
- Series B, Dec 22, 2009, $17M — New Enterprise Associates
- Series A, Sep 21, 2007, $8.9M — Mohr Davidow Ventures, New Enterprise Associates, GV, Genentech, Inc.

## Investors

- Mohr Davidow Ventures (https://capitalatlas.ai/funds/mohr-davidow-ventures) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C, Series D, Series E
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series C, Series D, Series E
- Genentech, Inc. — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C, Series D, Series E
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series E, Series F
- Illumina, Inc. — Series E
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series E, Series F
- Xfund (https://capitalatlas.ai/funds/xfund) — Series E
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series E
- EquityZen (https://capitalatlas.ai/funds/equityzen) — Series E
- ZWC Ventures (https://capitalatlas.ai/funds/zwc-ventures) — Series E
- Hong Shan — Series F
- FAM — Series F
- G Squared (https://capitalatlas.ai/funds/g-squared) — Series F
- Altimeter Capital (https://capitalatlas.ai/funds/altimeter-capital) — Series F
- Euclidean Capital — Series F
- NewView Capital (https://capitalatlas.ai/funds/newview-capital) — Series F